- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
VRIO Analysis of Merck Investing in Science-Based Business Abridged
Posted by Zachary Edwards on Mar-22-2018
The VRIO Analysis of Merck Investing in Science-Based Business Abridged will look at each of its internal resources one by one to assess whether these provide sustained competitive advantage. The Merck Investing in Science-Based Business Abridged VRIO Analysis also mentions at each stage whether these resources could be improved to provide a greater competitive advantage. Lastly, the resources analysed are summarised as to whether they offer sustained competitive advantage, has an unused competitive advantage, temporary competitive advantage, competitive parity or competitive disadvantage.
Valuable
- The Merck Investing in Science-Based Business Abridged VRIO Analysis shows that the financial resources of Merck Investing in Science-Based Business Abridged are highly valuable as these help in investing into external opportunities that arise. These also help Merck Investing in Science-Based Business Abridged in combating external threats.
- According to the VRIO Analysis of Merck Investing in Science-Based Business Abridged, its local food products are a valuable resource as these are highly differentiated. This makes the perceived value for these by customers high. These are also valued more than the competition by customers due to the differentiation in these products.
- The Merck Investing in Science-Based Business Abridged VRIO Analysis shows that Merck Investing in Science-Based Business Abridged's employees are a valuable resource to the firm. A significant portion of the workforce is highly trained, and this leads to more productive output for the organisation. The employees are also loyal, and retention levels for the organisation are high. All of this translates into greater value for the end consumers of Merck Investing in Science-Based Business Abridged's products.
- According to the VRIO Analysis of Merck Investing in Science-Based Business Abridged, its patents are a valuable resource as these allow the firm to sell its products without competitive interference. This results in greater revenue for Merck Investing in Science-Based Business Abridged. These patents also provide Merck Investing in Science-Based Business Abridged with licensing revenue when it licenses these patents out to other manufacturers.
- The Merck Investing in Science-Based Business Abridged VRIO Analysis shows that Merck Investing in Science-Based Business Abridged’s distribution network is a valuable resource. This helps it in reaching out to more and more customers. This ensures greater revenues for Merck Investing in Science-Based Business Abridged. It also ensures that promotion activities translate into sales as the products are easily available.
- According to the VRIO Analysis of Merck Investing in Science-Based Business Abridged, its cost structure is not a valuable resource. This is because the methods of production lead to greater costs than that of competition, which affects the overall profits of the firm. Therefore, its cost structure is a competitive disadvantage that needs to be worked on.
- The Merck Investing in Science-Based Business Abridged VRIO Analysis shows that the research and development at Merck Investing in Science-Based Business Abridged is not a valuable resource. This is because research and development are costing more than the benefits it provides in the form of innovation. There have been very few innovative features and breakthrough products in the past few years. Therefore, research and development are a competitive disadvantage for Merck Investing in Science-Based Business Abridged. It is recommended that the research and development teams are improved, and costs are cut for these.
Rare
- The financial resources of Merck Investing in Science-Based Business Abridged are found to be rare according to the VRIO Analysis of Merck Investing in Science-Based Business Abridged. Strong financial resources are only possessed by a few companies in the industry.
- The local food products are found to be not rare as identified by Merck Investing in Science-Based Business Abridged VRIO Analysis. These are easily provided in the market by other competitors. This means that competitors can use these resources in the same way as Merck Investing in Science-Based Business Abridged and inhibit competitive advantage. This means that the local food products result in competitive parity for Merck Investing in Science-Based Business Abridged. As this resource is valuable, Merck Investing in Science-Based Business Abridged can still make use of this resource.
- The employees of Merck Investing in Science-Based Business Abridged are a rare resource as identified by the VRIO Analysis of Merck Investing in Science-Based Business Abridged. These employees are highly trained and skilled, which is not the case with employees in other firms. The better compensation and work environment ensure that these employees do not leave for other firms.
- The patents of Merck Investing in Science-Based Business Abridged are a rare resource as identified by the Merck Investing in Science-Based Business Abridged VRIO Analysis. These patents are not easily available and are not possessed by competitors. This allows Merck Investing in Science-Based Business Abridged to use them without interference from the competition.
- The distribution network of Merck Investing in Science-Based Business Abridged is a rare resource as identified by the VRIO Analysis of Merck Investing in Science-Based Business Abridged. This is because competitors would require a lot of investment and time to come up with a better distribution network than that of Merck Investing in Science-Based Business Abridged. These are also possessed by very few firms in the industry.
Imitable
- The financial resources of Merck Investing in Science-Based Business Abridged are costly to imitate as identified by the Merck Investing in Science-Based Business Abridged VRIO Analysis. These resources have been acquired by the company through prolonged profits over the years. New entrants and competitors would require similar profits for a long period of time to accumulate these amounts of financial resources.
- The local food products are not that costly to imitate as identified by the VRIO Analysis of Merck Investing in Science-Based Business Abridged. These can be acquired by competitors as well if they invest a significant amount in research and development. These also do not require years long experience. Therefore, the local food products by Merck Investing in Science-Based Business Abridged provide it with a temporary competitive advantage that competitors can too acquire in the long run.
- The employees of Merck Investing in Science-Based Business Abridged are also not costly to imitate as identified by the Merck Investing in Science-Based Business Abridged VRIO Analysis. This is because other firms can also train their employees to improve their skills. These companies can also hire employees from Merck Investing in Science-Based Business Abridged by offering better compensation packages, work environment, benefits, growth opportunities etc. This makes the employees of Merck Investing in Science-Based Business Abridged a resource that provides a temporary competitive advantage. Competition can acquire these in the future.
- The patents of Merck Investing in Science-Based Business Abridged are very difficult to imitate as identified by the VRIO Analysis of Merck Investing in Science-Based Business Abridged. This is because it is not legally allowed to imitate a patented product. Similar resources to be developed and getting a patent for them is also a costly process.
- The distribution network of Merck Investing in Science-Based Business Abridged is also very costly to imitate by competition as identified by the Merck Investing in Science-Based Business Abridged VRIO Analysis. This has been developed over the years gradually by Merck Investing in Science-Based Business Abridged. Competitors would have to invest a significant amount if they are to imitate a similar distribution system.
Organisation
- The financial resources of Merck Investing in Science-Based Business Abridged are organised to capture value as identified by the VRIO Analysis of Merck Investing in Science-Based Business Abridged. These resources are used strategically to invest in the right places; making use of opportunities and combatting threats. Therefore, these resources prove to be a source of sustained competitive advantage for Merck Investing in Science-Based Business Abridged.
- The Patents of Merck Investing in Science-Based Business Abridged are not well organised as identified by the Merck Investing in Science-Based Business Abridged VRIO Analysis. This means that the organisation is not using these patents to their full potential. An unused competitive advantage exists that can be changed into a sustainable competitive advantage if Merck Investing in Science-Based Business Abridged starts selling patented products before the patents expire.
- The distribution network of Merck Investing in Science-Based Business Abridged is organised as identified by the VRIO Analysis of Merck Investing in Science-Based Business Abridged. Merck Investing in Science-Based Business Abridged uses this network to reach out to its customers by ensuring that products are available on all of its outlets. Therefore, these resources prove to be a source of sustained competitive advantage for Merck Investing in Science-Based Business Abridged.
From the VRIO Analysis of Merck Investing in Science-Based Business Abridged, it was identified that the financial resources and distribution network provide a sustained competitive advantage. The patents are a source of unused competitive advantage. There exists a temporary competitive advantage for employees. There exists a competitive parity for local food products. Lastly, the cost structure of Merck Investing in Science-Based Business Abridged is a competitive disadvantage. Research and Development is also a competitive disadvantage.
Warning! This article is only an example and cannot be used for research or reference purposes. If you need help with something similar, please submit your details here.
Liu Peng
5.0
The proposal would not have been approved yet if this service had not assisted me. Thanks for bringing me away from the boring activity.
Da Zu
5.0
The revision was taken into consideration and this service is always on time. I love the communication of this service by which the writer got what I wanted. Grateful!
Emile Arnaud
5.0
Not too pricey assignment writing service. I got what I was looking for. Great achievement. Recommended!
Hazel Branden
4.0
This paper writing service fulfills my expectations, which is why I always appoint it. The assignment was professionally done and I’m really happy. Thank you so much!
Next Articles
- Eli Lilly: The Evista Project Vrio Analysis
- PerkinElmer Developing Products In China For China Vrio Analysis
- Merck's U.S. Managed Distribution Program For The HIV Drug Crixivan Vrio Analysis
- Walton Instruments Manufacturing 1980 Vrio Analysis
- Alnylam Pharmaceuticals: Building Value From The IP Estate Vrio Analysis
- New Frontiers In Target Discovery And Validation Vrio Analysis
- Endius Inc.: Alternatives For Developing A New Medical Device Vrio Analysis
- Baxter Healthcare Corp.: ASAP Express, Spanish Version Vrio Analysis
- Genetic Testing And The Puzzles We Are Left To Solve (G): Secret Testing Vrio Analysis
- Manufacturing At ALZA: The Right Prescription? (B) Vrio Analysis
Previous Articles
- Novartis: The Challenge Of Success (B) Vrio Analysis
- Sorenson Research Co. (Abridged), Spanish Version Vrio Analysis
- Moore Medical Corp. Vrio Analysis
- MedSource Technologies, Portuguese Version Vrio Analysis
- Eli Lilly And Co.: Manufacturing Process Technology Strategy 1991, Spanish Version Vrio Analysis
- HydroCision, Inc. Vrio Analysis
- Merrimack Pharmaceuticals, Inc. (B) Vrio Analysis
- Pfizer's Centers For Therapeutic Innovation (CTI) Vrio Analysis
- Manufacturing At ALZA: The Right Prescription? (C) Vrio Analysis
- EBusiness@Novartis Vrio Analysis
Be a great writer or hire a greater one!
Academic writing has no room for errors and mistakes. If you have BIG dreams to score BIG, think out of the box and hire Case48 with BIG enough reputation.
Our Guarantees
Interesting Fact
Most recent surveys suggest that around 76 % students try professional academic writing services at least once in their lifetime!